89167-24-8Relevant articles and documents
ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
-
Page/Page column 183; 184, (2021/09/17)
Provided herein are novel compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.
A new route for the synthesis of 6-substituted [1,2,4]triazolo[4,3-a] pyrimidines
Krishnaraj, Thulasiraman,Muthusubramanian, Shanmugam
, p. E68-E70 (2014/11/07)
A new method of generating the fused heterocyclic system with bridgehead nitrogen, triazolo[4,3-a]pyrimidine, from 3-amino-1,2,4-triazole and unsaturated halo acids has been described.
ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS
-
Page/Page column 32, (2011/07/06)
The present invention relates to ethynyl compounds of formula wherein X, Y, Z, and R4 are as defined herein or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) and they are therefore useful for the treatment of diseases related to this receptor.